Evidence map›Paper›PMID 40545561›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome.

Victoria L Fleming, Brian C Helsel, Lauren T Ptomey, Benjamin L Handen, Sharon J Krinsky-McHale, Christy L Hom, Matthew Zammit, Davneet Minhas, Weiquan Luo, Charles Laymon and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Victoria L FlemingWaisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-6788-294X
Brian C HelselDepartment of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Lauren T PtomeyDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Benjamin L HandenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Sharon J Krinsky-McHaleDepartment of Psychology, New York Institute for Basic Research in Developmental Disabilities, New York, New York, USA.
Christy L HomDeparment of Psychiatry & Human Behavior, University of California, Irvine, Irvine, California, USA.
Matthew ZammitDepartment of Human Development and Family Studies, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Davneet MinhasDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Weiquan LuoDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Charles LaymonDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Joseph H LeeTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Sergievsky Center, and Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Ira LottDepartment of Pediatrics, University of California, Irvine School of Medicine, Irvine, California, USA.
Annie CohenBehavioral Health Service Line, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Beau M AncesDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Adam M BrickmanTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Sergievsky Center, and Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Margaret PulsiferDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Isabel C H ClareDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
H Diana RosaDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Florencia LaiDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jordan HarpDepartment of Neurology, University of Kentucky, Lexington, Kentucky, USA.
Fredrick SchmittDepartment of Neurology, University of Kentucky, Lexington, Kentucky, USA.
Julie PriceDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Shahid H ZamanDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine, University of California, Irvine School of Medicine, Irvine, California, USA.
Mark MapstoneDepartment of Neurology, University of California, Irvine School of Medicine, Irvine, California, USA.
Bradley T ChristianWaisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ozioma OkonkwoDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sigan L HartleyWaisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alzheimer's Biomarkers Consortium–Down Syndrome

Funding

Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, JOSEPH HYUNGWOO · 2020 to 2025
$103.7M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Biomarkers of Alzheimer's Disease in Adults with Down SyndromeU01AG051412 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOTT, IRA T., SCHUPF, NICOLE · 2015 to 2019
$26.3M
NiAD Supplement WashU Start UpU01AG051406 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTIAN, BRADLEY T, HANDEN, BENJAMIN L · 2015 to 2019
$21.3M
Lifestyle Risk and Resiliency Factors and Alzheimer’s Disease in Down syndromeR01AG070028 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sigan L Hartley, Christy Hom · 2020 to 2026
$4.6M
Assessment of Physical Activity for Alzheimer's Disease Research in Down SyndromeK01AG083130 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Brian Helsel · 2023 to 2026
$501k
Weight, inflammation, and Alzheimer's disease in Down syndromeF31AG085730 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI FLEMING, VICTORIA · 2024 to 2025
$73k
Eunice Kennedy Shriver National Institute of Child Health and Human Development P50HD105353NIA NIH HHS F31AG085730NIA NIH HHS K01 AG083130NIA NIH HHS K01AG083130NIA NIH HHS P30 AG066462NIA NIH HHS R01AG070028NIA NIH HHS U01AG051406NIA NIH HHS U01AG051412NIA NIH HHS U19AG068054NIHR Cambridge Biomedical Research Centre NIHR203312
6 · The paper itself

Abstract

introductionWeight loss has been linked to early Alzheimer's disease (AD) pathology, possibly through metabolic dysregulation. We examined changes in body mass index (BMI) in relation to AD biomarkers (amyloid beta [Aβ] and tau) and cognitive decline in adults with Down syndrome (DS). We hypothesized that BMI decline would track with early AD pathology and cognitive decline.

methodsAdults with DS (N = 467; M

resultsBMI declined with age-by-time (β = -0.014, p = 0.002) and baseline PET Aβ-by-time (β = -0.005, p = 0.002). On average, BMI decline began in the early 40s and was related to decline in memory and overall cognitive functioning. DISCUSSION: Weight loss is associated with the presence of Aβ and cognitive decline in adults with DS. Longitudinal studies need to clarify directionality and biological mechanisms. HIGHLIGHTS: Adults with Down syndrome (DS) are at an elevated risk for Down Syndrome assocaited Alzheimer's disease (DSAD). On average, adults with DS experience body mass index (BMI) decline beginning in their early 40s. Positron emission tomography amyloid beta deposition is associated with greater decline in BMI in adults with DS. Across time, AD-related memory declines are associated with BMI decline. BMI decline should be part of DSAD screening tools, as it is an important part of DSAD clinical disease expression.

Indexed as

Alzheimer DiseaseBody Mass IndexDown SyndromeAdultAgedAmyloid beta-PeptidesBiomarkersBrainCognitive DysfunctionFemaleHumansLongitudinal StudiesMaleMiddle AgedPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsABC‐DSAlzheimer's diseaseamyloid betacognitionDown syndrometrisomy 21weight loss

Identifiers

PMID40545561
PMCPMC12183108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.